Last reviewed · How we verify
Torsemide Tablets and Spironolactone Tablets
Torsemide is a thiazide-like diuretic that works by inhibiting the sodium-chloride cotransporter in the distal convoluted tubule of the kidneys, leading to increased urine production and reduced fluid volume. Spironolactone is a potassium-sparing diuretic that works by antagonizing the mineralocorticoid receptor, leading to increased sodium excretion and reduced potassium loss.
Torsemide is a thiazide-like diuretic that works by inhibiting the sodium-chloride cotransporter in the distal convoluted tubule of the kidneys, leading to increased urine production and reduced fluid volume. Spironolactone is a potassium-sparing diuretic that works by antagonizing the mineralocorticoid receptor, leading to increased sodium excretion and reduced potassium loss. Used for Edema associated with congestive heart failure, cirrhosis of the liver, or a nephrotic syndrome in adults, Hypertension.
At a glance
| Generic name | Torsemide Tablets and Spironolactone Tablets |
|---|---|
| Sponsor | Sarfez Pharmaceuticals, Inc. |
| Drug class | Loop diuretic and potassium-sparing diuretic |
| Target | Sodium-chloride cotransporter and Mineralocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Torsemide's mechanism of action is similar to that of other thiazide-like diuretics, such as hydrochlorothiazide. However, torsemide has a more potent diuretic effect and a longer duration of action. Spironolactone's mechanism of action is unique among diuretics, as it works by antagonizing the mineralocorticoid receptor rather than inhibiting sodium reabsorption.
Approved indications
- Edema associated with congestive heart failure, cirrhosis of the liver, or a nephrotic syndrome in adults
- Hypertension
Common side effects
- Hypokalemia
- Hyponatremia
- Dehydration
- Dizziness
- Headache
Key clinical trials
- Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone (PHASE3)
- A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (PHASE3)
- Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects (PHASE3)
- A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects (PHASE3)
- Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair
- Study of Drug Therapy for Pediatric Heart Failure
- Study of Innovative Drug Treatment Therapy for Pediatric Mitral Regurgitation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: